Innovation
With years of expertise, commitment, and resources, we continuously push the boundaries to create innovative healthcare solutions.
We are the pioneering leader in self-injection solutions, dedicated to enabling patients’ independence in their healthcare journey.
SHL Medical is the pioneering leader in designing, developing, and manufacturing self-injection solutions such as autoinjectors, pen injectors, and innovative specialty delivery systems for large-volume and high-viscosity formulations.
By partnering with leading pharma and biotech companies, we will continue to develop and supply products and services in order to support, engage, and oversee patients whose quality of life relies on innovative self-treatment therapies. This we do with one purpose in mind: Enabling patients' independence.
With a track record of over 50 launched combination products and 40 approved autoinjectors, we deliver proven reliability and quality to our customers, partners, and patients.
With years of expertise, commitment, and resources, we continuously push the boundaries to create innovative healthcare solutions.
Our commitment to quality drives us to deliver excellence, foster innovation, and lead the way for those we serve across the industry.
We are dedicated to continuous growth, consistently enhancing our people, services, and potential to achieve a more significant impact.
Roger Samuelsson establishes Scandinavian Health Limited (SHL Group).
1996
Launch of first autoinjector
The PenInject 2.25’s success inspires Roger’s vision of SHL as a
world-leading autoinjector solutions provider
2004
Design centers are founded in the US and Sweden
2007
On-site tooling capabilities are established
Commercial launch of SHL’s first DAI® project
The DAI becomes one of the most popular autoinjector formats on the market and lays the foundation for SHL’s success, supporting the modernization of self-injection treatment
The pre-configured Molly supports SHL's pharma partners in minimizing initial investments while maximizing development speed, later evolving into a modular platform with increased flexibility in design, development, and production.
New facility highlights SHL’s vertically integrated approach to drug delivery services, offering streamlined operations from product design to final delivery.
SHL sees several years of rapid employee growth, surpassing 2,000 people and signifying its arrival as a large-scale enterprise.
2016
Modularized fully automatic assembly and test equipment is introduced
Featuring a pre-installed needle, the groundbreaking Needle Isolation Technology radically simplifies how patients handle cartridge-based
injectors.
2018-19
Inauguration of Liufu site in Taiwan
SHL opens new combined building with modern office space with advanced manufacturing capacities
SHL opens new combined building with modern office space with advanced manufacturing capacities.
Switzerland headquarters is opened.
First Innovation Zed commercial partnership
Insulin pen add-on device InsulCheck Connect marks the first commercialization of an SHL add-on device for any injector, highlighting our ability to expand our portfolio. The device will later go on to win the 2021 Good Design Award
2021/2022
As part of our global footprint strategy, SHL launched plans for new manufacturing sites in Zug and USA, respectively. Through closer proximity with customers, the new sites signify our efforts to lessen global carbon footprint.
We are on an inspiring mission to embed sustainability into every aspect of our business, driving long-term growth and reinforcing our leadership in the medical sector. We are committed to reaching more patients while tackling critical issues such as climate change, resource scarcity, and human rights.
For questions, ideas, partnership inquiries, or further requests, please don't hesitate to reach out. We will get back to you.
Call us
Mon-Fri from 8:00AM-5:00PM (GMT+2)
+41 41 368 00 00
Visit us
You can find our office HQ at
Gubelstrasse 22
6300 Zug, Switzerland